Unlike living organisms, to avoid extinction, viruses need to hijack living host machineries to generate new viruses. The devastating respiratory virus, influenza A virus, utilize its hemagglutinin ...
Vaccines now in clinical trials can raise broad-spectrum antibodies against more than one form of hemagglutinin and provide protection against the flu strains that have been most troublesome from a ...
Unlike living organisms, to avoid extinction, viruses need to hijack living host machineries to generate new viruses. The devastating respiratory virus, influenza A virus, utilize its hemagglutinin ...
In a recent study published in Emerging Infectious Diseases, researchers performed a quantitative assessment of the age-stratified seroprevalence of hemagglutination inhibition (HAI) antibodies ...
Researchers conducted a randomized clinical trial to compare the immunogenicity and safety profile of RIV (45 μg of recombinant hemagglutinin per strain) with that of the standard-dose (15 μg of ...
The ever-changing 'head' of an influenza virus protein has an unexpected Achilles heel, report scientists. The team discovered the structure of a naturally occurring human antibody that recognizes and ...
The back-and-forth battle between influenza viruses and humans is defined by diversity. We fight previously unseen pathogens with a diverse repertoire of antibodies, and influenza viruses evade our ...
Cell-culture–derived influenza vaccines may enable a closer antigenic match to circulating strains of influenza virus by avoiding egg-adapted mutations. We evaluated the efficacy of a ...
The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was monovalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results